H2O logo


Start Date
End Date
IMI2 - Call 18
Grant agreement number

Type of Action: 
RIA (Research and Innovation Action)

IMI Funding
10 476 687
EFPIA in kind
11 263 000
Associated Partners
168 000
71 250
Total Cost
21 978 938


Today, many measures of disease (and disease outcomes) are based largely on input from clinicians. As such they do not fully capture patients’ own experiences of the disease and its impact on their lives.

The aim of H2O is to create ‘health outcomes observatories’ that will amplify the patient voice both in their own healthcare and in healthcare systems more broadly.

The health outcomes observatories will work by providing patients with digital tools, including an app, to report their health outcomes in a standardised way. Patients will always maintain control of their own data and will decide who can access it. At one level, the information will help clinicians and patients to make better decisions on their care.

Meanwhile, the data will be anonymised and tracked so that individual patients and their clinicians can compare their progress with other patients with similar health issues. This aggregated data could also form the basis of research into new, innovative, evidence-based treatments.

The project will focus on setting up health outcomes observatories in four countries (Germany, Spain, the Netherlands, and Austria) covering three disease areas: diabetes, inflammatory bowel disease, and cancer. In the longer term, the project hopes that more observatories, covering a wider range of disease areas, will open up across Europe.

Participants Show participants on map

EFPIA companies
  • Abbvie Inc, North Chicago, Illinois, United States
  • Astrazeneca AB, Södertälje, Sweden
  • Eli Lilly And Company LTD, Basingstoke, United Kingdom
  • F. Hoffmann-La Roche AG, Basel, Switzerland
  • Medtronic International Trading SARL, Tolochenaz, Switzerland
  • Novartis Pharma AG, Basel, Switzerland
  • Pfizer Limited, Sandwich, Kent , United Kingdom
  • Sanofi-Aventis Recherche & Developpement, Chilly Mazarin, France
  • Takeda Pharmaceuticals International AG, Glattpark-Opfikon (Zurich), Switzerland
Universities, research organisations, public bodies, non-profit groups
  • Charite - Universitaetsmedizin Berlin, Berlin, Germany
  • Erasmus Universitair Medisch Centrum Rotterdam, Rotterdam, Netherlands
  • Forum Des Patients Europeens, 1040, Belgium
  • Institut Catala De La Salut, Barcelona, Spain
  • Katholieke Universiteit Leuven, Leuven, Belgium
  • King'S College London, London, United Kingdom
  • Medizinische Universitaet Wien, Vienna, Austria
  • Region Stockholm, Stockholm, Sweden
  • Stichting Integraal Kankercentrum Nederland, Utrecht, Netherlands
  • The European Institute For Innovation Through Health Data, Gent, Belgium
  • Universita Vita-Salute San Raffaele, Milano, Italy
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • Team - It Research SL, Barcelona, Spain
  • The Hyve BV, Utrecht, Netherlands
Associated partners
  • Jdrf International, New York, United States
  • Trial Nation, Copenhagen, Denmark
Third parties
  • Fundacio Privada Institut D'Investigacio Oncologica De Vall-Hebron (Vhio), Barcelona, Spain
Project leader
Meni Styliadou
Takeda Pharmaceuticals